Helen J Lachmann

List of Publications by Year
in descending order

266 papers	24,030 citations	81 h-index	148 g-index
		5896	8167
273 all docs	273 docs citations	273 times ranked	14614 citing authors

#	Article	IF	Citations
1	Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy. Heart, 2022, 108, 474-478.	2.9	8
2	Clinical Importance of Left Atrial Infiltration in Cardiac TransthyretinÂAmyloidosis. JACC: Cardiovascular Imaging, 2022, 15, 17-29.	5.3	67
3	The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study. Efficacy and Mechanism Evaluation, 2022, 9, 1-106.	0.7	1
4	Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. European Heart Journal, 2022, 43, 2622-2632.	2.2	27
5	A <scp>UK</scp> consensus algorithm for early treatment modification in newly diagnosed systemic lightâ€chain amyloidosis. British Journal of Haematology, 2022, , .	2.5	2
6	The experience of hereditary apolipoprotein A-I amyloidosis at the UK National Amyloidosis Centre. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 237-244.	3.0	5
7	The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukinâ€1 Mediated Autoinflammatory Diseases: Cryopyrinâ€Associated Periodic Syndromes, Tumour Necrosis Factor Receptorâ€Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukinâ€1 Receptor Antagonist. Arthritis and Rheumatology, 2022,	5.6	14
8	The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Annals of the Rheumatic Diseases, 2022, 81, 907-921.	0.9	38
9	Pericarditis and Autoinflammation: A Clinical and Genetic Analysis of Patients With Idiopathic Recurrent Pericarditis and Monogenic Autoinflammatory Diseases at a National Referral Center. Journal of the American Heart Association, 2022, 11, .	3.7	15
10	Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. European Journal of Heart Failure, 2022, 24, 1700-1712.	7.1	26
11	INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 783-791.e4.	3.8	16
12	Defining colchicine resistance/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. Rheumatology, 2021, 60, 3799-3808.	1.9	29
13	COVID-19 and autoinflammatory diseases: prevalence and outcomes of infection and early experience of vaccination in patients on biologics. Rheumatology Advances in Practice, 2021, 5, rkab043.	0.7	15
14	Autologous stem cell transplantation vs bortezomib based chemotheraphy for the firstâ€line treatment of systemic light chain amyloidosis in the UK. European Journal of Haematology, 2021, 106, 537-545.	2.2	4
15	Renal transplant outcomes in amyloidosis. Nephrology Dialysis Transplantation, 2021, 36, 355-365.	0.7	20
16	One Hundred Cases of Localized Laryngeal Amyloidosis â€•Evidence for Future Management. Laryngoscope, 2021, 131, E1912-E1917.	2.0	18
17	Cardiac Magnetic Resonanceâ€“Derived Extracellular Volume Mapping for the Quantification of Hepatic and Splenic Amyloid. Circulation: Cardiovascular Imaging, 2021, 14, CIRCIMAGING121012506.	2.6	19
18	Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib. Blood Cancer Journal, 2021, 11, 118.	6.2	15

#	Article	IF	Citations
19	Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of realâ€world longitudinal data. British Journal of Haematology, 2021, 194, 587-597.	2.5	4
20	Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 230.	7.4	139
21	99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis. European Heart Journal Cardiovascular Imaging, 2021, 22, 1304-1311.	1.2	26
22	Urinary retinol binding protein predicts renal outcome in systemic immunoglobulin lightâ€chain (AL) amyloidosis. British Journal of Haematology, 2021, 194, 1016-1023.	2.5	3
23	Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. Blood, 2021, 138, 2721-2721.	1.4	5
24	British kindred with dominant FMF associated with high incidence of AA amyloidosis caused by novel MEFV variant, and a review of the literature. Rheumatology, 2020, 59, 554-558.	1.9	8
25	IL-36 Promotes Systemic IFN-I Responses in Severe Forms of Psoriasis. Journal of Investigative Dermatology, 2020, 140, 816-826.e3.	0.7	64
26	Noncontrast Magnetic Resonance for theÂDiagnosis of Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 69-80.	5.3	125
27	Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage. ESC Heart Failure, 2020, 7, 3942-3949.	3.1	22
28	The Authors Reply:. JACC: Cardiovascular Imaging, 2020, 13, 1294-1295.	5.3	1
29	Evidence of B Cell Clonality and Investigation Into Properties of the IgM in Patients With Schnitzler Syndrome. Frontiers in Immunology, 2020, 11, 569006.	4.8	6
30	Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. New England Journal of Medicine, 2020, 383, 2628-2638.	27.0	580
31	Cardiovascular disease risk assessment in patients with familial Mediterranean fever related renal amyloidosis. Scientific Reports, 2020, 10, 18374.	3.3	5
32	Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis. JAMA Dermatology, 2020, 156, 1216.	4.1	18
33	Familial Mediterranean fever, from pathogenesis to treatment: a contemporary review. Turkish Journal of Medical Sciences, 2020, 50, 1591-1610.	0.9	70
34	Two types of systemic amyloidosis in a single patient. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 275-276.	3.0	6
35	Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 200-205.	3.0	12
36	The value of screening biopsies in lightâ€chain (AL) and transthyretin (ATTR) amyloidosis. European Journal of Haematology, 2020, 105, 352-356.	2.2	10

#	Article	IF	Citations
37	ISSAID/EMQN Best Practice Guidelines for the Genetic Diagnosis of Monogenic Autoinflammatory Diseases in the Next-Generation Sequencing Era. Clinical Chemistry, 2020, 66, 525-536.	3.2	43
38	Amyloidosis Diagnosed in Solid Organ Transplant Recipients. Transplantation, 2020, 104, 415-420.	1.0	7
39	Cholesterol metabolism drives regulatory B cell IL-10 through provision of geranylgeranyl pyrophosphate. Nature Communications, 2020, 11, 3412.	12.8	47
40	Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. European Heart Journal, 2020, 41, 1439-1447.	2.2	108
41	Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid lightâ€chain amyloidosis. British Journal of Haematology, 2020, 189, 643-649.	2.5	25
42	Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria. Haematologica, 2020, 105, 1405-1413.	3.5	10
43	The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis. Blood Cancer Journal, 2020, 10, 60.	6.2	7
44	A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial. Trials, 2020, 21, 158.	1.6	7
45	TRAP1 chaperone protein mutations and autoinflammation. Life Science Alliance, 2020, 3, e201900376.	2.8	9
46	Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS). Rare Diseases of the Immune System, 2020, , 235-245.	0.1	0
47	The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis. Blood, 2020, 136, 40-40.	1.4	1
48	The Prognostic Importance of the 6-Minute Walk Test in AL Amyloidosis. Blood, 2020, 136, 16-17.	1.4	2
49	Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy. British Journal of Haematology, 2019, 187, 638-641.	2.5	35
50	A 24â€year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom. British Journal of Haematology, 2019, 187, 642-652.	2.5	29
51	Retrospective case series describing the efficacy, safety and cost-effectiveness of a vial-sharing programme for canakinumab treatment for paediatric patients with cryopyrin-associated periodic syndrome. Pediatric Rheumatology, 2019, 17, 36.	2.1	5
52	Exploratory Study of <scp>MYD</scp>88 L265P, Rare <scp>NLRP</scp>3 Variants, and Clonal Hematopoiesis Prevalence in Patients With Schnitzler Syndrome. Arthritis and Rheumatology, 2019, 71, 2121-2125.	5.6	33
53	Paraprotein-related renal disease. Medicine, 2019, 47, 666-671.	0.4	0
54	A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood, 2019, 134, 2271-2280.	1.4	130

#	Article	IF	Citations
55	How to prescribe a genetic test for the diagnosis of autoinflammatory diseases?. Presse Medicale, 2019, 48, e49-e59.	1.9	7
56	Rapid and Sustained Longâ€Term Efficacy and Safety of Canakinumab in Patients With Cryopyrinâ€Associated Periodic Syndrome Ages Five Years and Younger. Arthritis and Rheumatology, 2019, 71, 1955-1963.	5.6	34
57	Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers. British Journal of Haematology, 2019, 186, 460-470.	2.5	15
58	Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation, 2019, 140, 16-26.	1.6	288
59	Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases, 2019, 78, 1025-1032.	0.9	300
60	The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the ClinicalÂDiagnosis of Inborn Errors of Immunity. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1763-1770.	3.8	381
61	The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis. Journal of Pathology: Clinical Research, 2019, 5, 145-153.	3.0	46
62	Corticosteroid, Other Biologic and Small Molecule Therapies in Systemic Autoinflammatory Disorders. , 2019, , 775-791.		0
63	OP0254â€…CANAKINUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RECURRENT FEVER SYNDROMES: RESULTS FROM A PHASE 3 TRIAL (CLUSTER). , 2019, , .		0
64	OP0258â€…LESSON FROM EUROFEVER REGISTRY AFTER THE FIRST TEN YEARS OF ENROLLMENT. , 2019, , .		0
65	Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic <scp>AL</scp> amyloidosis. British Journal of Haematology, 2019, 185, 977-980.	2.5	5
66	An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptorâ€“associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. Journal of Rheumatology, 2019, 46, 429-436.	2.0	16
67	Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience. Human Mutation, 2019, 40, 90-96.	2.5	29
68	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature Reviews Nephrology, 2019, 15, 45-59.	9.6	330
69	Cardiac Structural and Functional Consequences of Amyloid Deposition byÂCardiac Magnetic Resonance andÂEchocardiography and TheirÂPrognosticÂRoles. JACC: Cardiovascular Imaging, 2019, 12, 823-833.	5.3	113
70	The UK Experience of Renal Transplantation in AL Amyloidosis. Blood, 2019, 134, 2206-2206.	1.4	0
71	Adult-onset tumour necrosis factor receptor-associated periodic syndrome presenting as transfusion-dependent refractory haemophagocytosis. Rheumatology, 2018, 57, 582-583.	1.9	3
72	Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome. Blood, 2018, 131, 974-981.	1.4	83

#	Article	IF	Citations
73	Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis. Haematologica, 2018, 103, e165-e168.	3.5	44
74	The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey. Pediatric Rheumatology, 2018, 16, 19.	2.1	35
75	CMR-Verified Regression of Cardiac AL Amyloid After Chemotherapy. JACC: Cardiovascular Imaging, 2018, 11, 152-154.	5.3	90
76	Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis. British Journal of Haematology, 2018, 182, 145-148.	2.5	20
77	A new staging system for cardiac transthyretin amyloidosis. European Heart Journal, 2018, 39, 2799-2806.	2.2	396
78	Tocilizumab for the Treatment of Mevalonate Kinase Deficiency. Case Reports in Pediatrics, 2018, 2018, 1-6.	0.4	7
79	Secondary, AA, Amyloidosis. Rheumatic Disease Clinics of North America, 2018, 44, 585-603.	1.9	121
80	Complement receptor CD46 co-stimulates optimal human CD8+ T cell effector function via fatty acid metabolism. Nature Communications, 2018, 9, 4186.	12.8	75
81	A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial. Trials, 2018, 19, 465.	1.6	15
82	Cryopyrin-Associated Periodic Fever Syndrome and the Nervous System. Current Treatment Options in Neurology, 2018, 20, 43.	1.8	22
83	Successful treatment of systemic AA amyloidosis associated with underlying Hodgkin lymphoma. British Journal of Haematology, 2018, 182, 619-619.	2.5	3
84	Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. New England Journal of Medicine, 2018, 378, 1908-1919.	27.0	327
85	In silico validation of the Autoinflammatory Disease Damage Index. Annals of the Rheumatic Diseases, 2018, 77, 1599-1605.	0.9	27
86	Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. Annals of the Rheumatic Diseases, 2018, 77, 1558-1565.	0.9	114
87	Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis. British Journal of Haematology, 2018, 183, 557-563.	2.5	15
88	i112â€ƒAuto-inflammatory diseases. Rheumatology, 2018, 57, .	1.9	0
89	Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine. Blood, 2018, 132, 761-764.	1.4	25
90	Autosomal dominant familial Mediterranean fever in Northern European Caucasians associated with deletion of p.M694 residueâ€"a case series and genetic exploration. Rheumatology, 2017, 56, 209-213.	1.9	49

#	Article	IF	Citations
91	High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot study. Sleep Medicine, 2017, 32, 191-197.	1.6	5
92	Renal Amyloidosis Associated With 5 NovelÂVariants in the Fibrinogen A Alpha Chain Protein. Kidney International Reports, 2017, 2, 461-469.	0.8	25
93	Development of the autoinflammatory disease damage index (ADDI). Annals of the Rheumatic Diseases, 2017, 76, 821-830.	0.9	68
94	Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Annals of the Rheumatic Diseases, 2017, 76, 173-178.	0.9	96
95	A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 72-73.	3.0	3
96	A baffling case of severe systemic inflammation. Putting the pieces together: genes, environment and triggers. Rheumatology, 2017, 56, 853-854.	1.9	1
97	Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome. Annals of the Rheumatic Diseases, 2017, 76, 303-309.	0.9	30
98	Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. European Heart Journal, 2017, 38, 1905-1908.	2.2	144
99	Carpal Tunnel Biopsy Identifying Transthyretin Amyloidosis. Arthritis and Rheumatology, 2017, 69, 2051-2051.	5.6	5
100	Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. European Heart Journal Cardiovascular Imaging, 2017, 18, 1344-1350.	1.2	124
101	Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Annals of the Rheumatic Diseases, 2017, 76, 942-947.	0.9	175
102	Pitfalls in conducting prospective trials in stage III cardiac amyloidosis â€“ experience from the REVEAL study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 250-252.	3.0	2
103	Immunoparesis defined by heavy+light chain suppression is a novel marker of longâ€term outcomes in cardiac AL amyloidosis. British Journal of Haematology, 2017, 179, 575-585.	2.5	16
104	International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. Rheumatology, 2017, 56, 2102-2108.	1.9	84
105	Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reductionÂisÂthe crucial factor. Kidney International, 2017, 92, 1476-1483.	5.2	22
106	Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 189-193.	3.0	17
107	008â€…Demonstration of cardiac AL amyloidosis regression after succesful chemotherapy. a CMR study. Heart, 2017, 103, A7.1-A7.	2.9	0
108	Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 162-166.	3.0	61

#	Article	IF	Citations
109	International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptorâ€“Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. Arthritis Care and Research, 2017, 69, 578-586.	3.4	75
110	Muckleâ€Wells syndrome: a rare hereditary cryopyrinâ€associated periodic syndrome. International Journal of Rheumatic Diseases, 2017, 20, 1873-1875.	1.9	5
111	Periodic fever syndromes. Best Practice and Research in Clinical Rheumatology, 2017, 31, 596-609.	3.3	84
112	Late-Onset Cryopyrin-Associated Periodic Syndromes Caused by Somatic NLRP3 Mosaicismâ€”UK Single Center Experience. Frontiers in Immunology, 2017, 8, 1410.	4.8	109
113	A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry. Orphanet Journal of Rare Diseases, 2017, 12, 167.	2.7	52
114	Autoinflammatory Disorders. , 2017, , 393-435.		1
115	Clinical impact of a targeted next-generation sequencing gene panel for autoinflammation and vasculitis. PLoS ONE, 2017, 12, e0181874.	2.5	69
116	Reply to: Long-term tocilizumab efficacy in a patient with psoriatic arthritis and AA amyloidosis. Dinoia et al. Clinical and Experimental Rheumatology, 2017, 35, 171.	0.8	10
117	054â€ƒAdult Periodic Fevers, Apthous Ulceration, Pharyngitis and Adenitis: A Single-Centre Experience. Rheumatology, 2016, , .	1.9	0
118	Comparison of Free Light Chain Assays. American Journal of Clinical Pathology, 2016, 146, 78-85.	0.7	8
119	The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. Arthritis and Rheumatology, 2016, 68, 2795-2805.	5.6	168
120	Brief Report: Association of Tumor Necrosis Factor Receptorâ€“Associated Periodic Syndrome With Gonosomal Mosaicism of a Novel 24â€Nucleotide TNFRSF1A Deletion. Arthritis and Rheumatology, 2016, 68, 2044-2049.	5.6	49
121	Trapped without a diagnosis: Tumour necrosis factor receptor-associated periodic syndrome (TRAPS). Practical Neurology, 2016, 16, 304-307.	1.1	5
122	Response to Letters Regarding Article, â€œPrognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosisâ€. Circulation, 2016, 133, e450-1.	1.6	4
123	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 2016, 133, 2404-2412.	1.6	1,335
124	When is familial Mediterranean fever 'severe'?. Nature Reviews Rheumatology, 2016, 12, 256-258.	8.0	7
125	Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis. Nephrology Dialysis Transplantation, 2016, 33, gfw375.	0.7	18
126	European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin Mâ€“Related Light Chain Amyloidosis. Journal of Clinical Oncology, 2016, 34, 2037-2045.	1.6	60

#	Article	IF	Citations
127	T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4 ⁺ T cells. Science, 2016, 352, aad1210.	12.6	395
128	Autoinflammatory Syndromes in Children. Indian Journal of Pediatrics, 2016, 83, 242-247.	0.8	14
129	Non-Hodgkin's lymphoma causing light-chain (AL) amyloidosis. British Journal of Hospital Medicine (London, England: 2005), 2016, 77, 188-189.	0.5	0
130	Performance of Different Diagnostic Criteria for Familial Mediterranean Fever in Children with Periodic Fevers: Results from a Multicenter International Registry. Journal of Rheumatology, 2016, 43, 154-160.	2.0	52
131	A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood, 2015, 126, 612-615.	1.4	334
132	Natural history and outcome of light chain deposition disease. Blood, 2015, 126, 2805-2810.	1.4	103
133	Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis. Haematologica, 2015, 100, 1469-1476.	3.5	14
134	Long-Term Complications of Familial Mediterranean Fever. Rare Diseases of the Immune System, 2015, , 91-105.	0.1	1
135	T1 mapping and survival in systemic light-chain amyloidosis. European Heart Journal, 2015, 36, 244-251.	2.2	310
136	A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. European Heart Journal, 2015, 36, 1098-1105.	2.2	129
137	Autoinflammatory syndromes as causes of fever of unknown origin. Clinical Medicine, 2015, 15, 295-298.	1.9	13
138	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Annals of the Rheumatic Diseases, 2015, 74, 799-805.	0.9	215
139	Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Annals of the Rheumatic Diseases, 2015, 74, 2043-2049.	0.9	180
140	A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue. Journal of Clinical Pathology, 2015, 68, 314-317.	2.0	95
141	Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Annals of the Rheumatic Diseases, 2015, 74, 635-641.	0.9	145
142	Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study. Radiology, 2015, 277, 388-397.	7.3	146
143	Recommendations for the management of autoinflammatory diseases. Annals of the Rheumatic Diseases, 2015, 74, 1636-1644.	0.9	239
144	Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study. Lancet Haematology,the, 2015, 2, e241-e250.	4.6	105

#	Article	IF	Citations
145	A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 26-30.	3.0	4
146	Guidelines on the diagnosis and investigation of AL amyloidosis. British Journal of Haematology, 2015, 168, 207-218.	2.5	122
147	Guidelines on the management of <scp>AL</scp> amyloidosis. British Journal of Haematology, 2015, 168, 186-206.	2.5	112
148	Paraprotein-related renal disease and amyloid. Medicine, 2015, 43, 533-537.	0.4	1
149	Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation, 2015, 132, 1570-1579.	1.6	442
150	Emerging treatments for amyloidosis. Kidney International, 2015, 87, 516-526.	5.2	25
151	Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. Journal of Clinical Investigation, 2015, 125, 4196-4211.	8.2	258
152	Amyloidosis and the Respiratory Tract. , 2015, , 91-111.		0
153	Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature. Clinical and Experimental Rheumatology, 2015, 33, S46-53.	0.8	29
154	Infusion of Pharmaceutical-Grade Natural Human C-Reactive Protein Is Not Proinflammatory in Healthy Adult Human Volunteers. Circulation Research, 2014, 114, 672-676.	4.5	63
155	Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. European Heart Journal Cardiovascular Imaging, 2014, 15, 1289-1298.	1.2	184
156	Validation of the Auto-Inflammatory Diseases Activity Index (AIDAI) for hereditary recurrent fever syndromes. Annals of the Rheumatic Diseases, 2014, 73, 2168-2173.	0.9	120
157	The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Annals of the Rheumatic Diseases, 2014, 73, 2160-2167.	0.9	256
158	Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature Recommendations. Human Mutation, 2014, 35, E2403-E2412.	2.5	220
159	Clinical characteristics and SAP scintigraphic findings in 10 patients with AGel amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 276-281.	3.0	5
160	Brief Report: Wholeâ€Exome Sequencing Revealing Somatic NLRP3 Mosaicism in a Patient With Chronic Infantile Neurologic, Cutaneous, Articular Syndrome. Arthritis and Rheumatology, 2014, 66, 197-202.	5.6	44
161	Native T1 Mapping in Transthyretin Amyloidosis. JACC: Cardiovascular Imaging, 2014, 7, 157-165.	5.3	339
162	Renal cell carcinoma presenting as AA amyloidosis: a case report and review of the literature. CEN Case Reports, 2014, 3, 68-74.	0.9	7

#	Article	IF	Citations
163	Lenalidomide and dexamethasone for systemic <scp>AL</scp> amyloidosis following prior treatment with thalidomide or bortezomib regimens. British Journal of Haematology, 2014, 166, 842-848.	2.5	47
164	Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience. Rheumatology, 2014, 53, 665-670.	1.9	35
165	MEFVmutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. Annals of the Rheumatic Diseases, 2014, 73, 455-461.	0.9	101
166	A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia, 2014, 28, 2304-2310.	7.2	89
167	CMR-Based Differentiation of AL and ATTR Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2014, 7, 133-142.	5.3	242
168	Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting. Haematologica, 2014, 99, e260-e263.	3.5	14
169	Two types of amyloid in a single heart. Blood, 2014, 124, 3025-3027.	1.4	24
170	The Prognostic Significance of Phenotypically â€˜Normalâ€™ Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma. Blood, 2014, 124, 2073-2073.	1.4	1
171	Clinical characteristics in subjects with NLRP3 V198M diagnosed at a single UK center and a review of the literature. Arthritis Research and Therapy, 2013, 15, R30.	3.5	53
172	A New Era in the Treatment of Amyloidosis?. New England Journal of Medicine, 2013, 369, 866-868.	27.0	10
173	Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Annals of the Rheumatic Diseases, 2013, 72, 678-685.	0.9	350
174	Inflammatory Bowel Disease and Systemic AA Amyloidosis. Digestive Diseases and Sciences, 2013, 58, 1689-1697.	2.3	32
175	Renal Transplantation in Systemic Amyloidosisâ€”Importance of Amyloid Fibril Type and Precursor Protein Abundance. American Journal of Transplantation, 2013, 13, 433-441.	4.7	74
176	Schnitzler's syndrome: diagnosis, treatment, and followâ€up. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 562-568.	5.7	224
177	Brief Report: AA Amyloidosis Complicating the Hereditary Periodic Fever Syndromes. Arthritis and Rheumatism, 2013, 65, 1116-1121.	6.7	90
178	Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome. Journal of the American Heart Association, 2013, 2, e000098.	3.7	275
179	Systemic Amyloidosis in <scp>E</scp>ngland: an epidemiological study. British Journal of Haematology, 2013, 161, 525-532.	2.5	222
180	Clinical profile and treatment outcomes of immunoglobulin <scp>D</scp> associated <scp>AL</scp> amyloidosis. British Journal of Haematology, 2013, 162, 856-858.	2.5	1

#	Article	IF	Citations
181	A prospective study of nutritional status in immunoglobulin light chain amyloidosis. Haematologica, 2013, 98, 136-140.	3.5	27
182	A Retrospective Patient Chart Review and Survey in Patients with Cryopyrin-associated Periodic Syndromes Treated with Anakinra. Journal of Health Economics and Outcomes Research, 2013, 1, 123-133.	1.2	0
183	Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. Annals of the Rheumatic Diseases, 2012, 71, 2035-2043.	0.9	69
184	Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood, 2012, 119, 4387-4390.	1.4	250
185	How not to miss autoinflammatory diseases masquerading as urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1465-1474.	5.7	74
186	An International registry on Autoinflammatory diseases: the Eurofever experience. Annals of the Rheumatic Diseases, 2012, 71, 1177-1182.	0.9	158
187	Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. European Heart Journal, 2012, 33, 1120-1127.	2.2	143
188	The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. American Heart Journal, 2012, 164, 72-79.	2.7	41
189	Systemic AA Amyloidosis. Sub-Cellular Biochemistry, 2012, 65, 541-564.	2.4	32
190	The Role of Immunological Assessment in Patients With Acute Kidney Injury and Possible Myeloma. Advances in Chronic Kidney Disease, 2012, 19, 287-290.	1.4	0
191	Patterns of late gadolinium enhancement in 94 patients with AL or transthyretin cardiac amyloidosis. Journal of Cardiovascular Magnetic Resonance, 2012, 14, .	3.3	7
192	The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nature Reviews Nephrology, 2012, 8, 43-51.	9.6	226
193	Hereditary lysozyme amyloidosis â€“ phenotypic heterogeneity and the role of solid organ transplantation. Journal of Internal Medicine, 2012, 272, 36-44.	6.0	59
194	A Matched Comparison of Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in the Treatment of Mayo Cardiac Stage III Patients with AL Amyloidosis.. Blood, 2012, 120, 2966-2966.	1.4	2
195	Continuous Therapy with Lenalidomide Correlates with Improved Progression Free Survival in Heavily Pre-Treated Patients with AL Amyloidosis.. Blood, 2012, 120, 2978-2978.	1.4	0
196	Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis. Blood, 2012, 120, 4074-4074.	1.4	1
197	Amyloidogenicity and Clinical Phenotype Associated with Five Novel Mutations in Apolipoprotein A-I. American Journal of Pathology, 2011, 179, 1978-1987.	3.8	111
198	A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis. Journal of Cardiology Cases, 2011, 4, e93-e97.	0.5	29

#	Article	IF	Citations
199	Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis. Haematologica, 2011, 96, 1079-1080.	3.5	31
200	Paraprotein-related renal disease and amyloid. Medicine, 2011, 39, 481-485.	0.4	0
201	The Emerging Role of Interleukin-1Î² in Autoinflammatory Diseases. Current Allergy and Asthma Reports, 2011, 11, 361-368.	5.3	29
202	Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Research and Therapy, 2011, 13, R202.	3.5	106
203	The emerging role of interleukinâ€1Î² in autoinflammatory diseases. Arthritis and Rheumatism, 2011, 63, 314-324.	6.7	82
204	A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference. Annals of the Rheumatic Diseases, 2011, 70, 309-314.	0.9	70
205	Outcome in Renal AL Amyloidosis After Chemotherapy. Journal of Clinical Oncology, 2011, 29, 674-681.	1.6	126
206	An unusual phenotype in Muckle-Wells syndrome associated with NLRP3 E311K. Rheumatology, 2011, 50, 419-420.	1.9	6
207	IL-1 Inhibition in Cryopyrin-Associated Periodic Syndrome and Beyond: A Million Dollar Question about the Injection Schedule of Biotherapies. Dermatology, 2011, 223, 119-121.	2.1	2
208	Familial Mediterranean fever caused by homozygous E148Q mutation complicated by Budd-Chiari syndrome and polyarteritis nodosa. Rheumatology, 2011, 50, 624-626.	1.9	10
209	Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Annals of the Rheumatic Diseases, 2011, 70, 2095-2102.	0.9	182
210	ALchemy - A Large Prospective â€˜Real World' Study of Chemotherapy in AL Amyloidosis. Blood, 2011, 118, 992-992.	1.4	26
211	Treatment of Inflammasome-Related Disorders. , 2011, , 209-220.		0
212	Complete and Very Good Partial Responses Are Attainable Endpoints in Elderly Patients (>75 years) with AL Amyloidosis and Are Associated with Improved Overall Survival,. Blood, 2011, 118, 3975-3975.	1.4	1
213	Cyclophosphamide, Bortezomib and Dexamethasone (CVD) Therapy in AL Amyloidosis Is Associated with High Clonal Response Rates and Prolonged Progression Free Survival,. Blood, 2011, 118, 3978-3978.	1.4	1
214	Hereditary fibrinogen A Î±-chain amyloidosis: clinical phenotype and role of liver transplantation. Blood, 2010, 115, 4313-4313.	1.4	16
215	Solid Organ Transplantation in AL Amyloidosis. American Journal of Transplantation, 2010, 10, 2124-2131.	4.7	109
216	Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. British Journal of Haematology, 2010, 148, 760-767.	2.5	106

#	Article	IF	Citations
217	Renal amyloidosis. British Journal of Hospital Medicine (London, England: 2005), 2010, 71, 83-86.	0.5	9
218	Neurologic manifestations of the cryopyrin-associated periodic syndrome. Neurology, 2010, 74, 1267-1270.	1.1	72
219	Secondary, AA, Amyloidosis. , 2010, , 179-189.		2
220	Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases. Blood, 2010, 116, 3958-3958.	1.4	0
221	In vivo regulation of interleukin 1Î² in patients with cryopyrin-associated periodic syndromes. Journal of Experimental Medicine, 2009, 206, 1029-1036.	8.5	270
222	Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation. Nature Clinical Practice Cardiovascular Medicine, 2009, 6, 128-133.	3.3	17
223	Diagnosis, Pathogenesis, Treatment, and Prognosis of Hereditary Fibrinogen AÎ±-Chain Amyloidosis. Journal of the American Society of Nephrology: JASN, 2009, 20, 444-451.	6.1	145
224	Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome. New England Journal of Medicine, 2009, 360, 2416-2425.	27.0	754
225	Developments in the scientific and clinical understanding of autoinflammatory disorders. Arthritis Research and Therapy, 2009, 11, 212.	3.5	34
226	Transient Post Chemotherapy Rise in NT Pro-BNP in AL Amyloidosis : Implications for Organ Response Assessment.. Blood, 2009, 114, 1791-1791.	1.4	4
227	A New Staging System for AL Amyloidosis Incorporating Serum Free Light Chains, cardiac Troponin-T and NT-ProBNP.. Blood, 2009, 114, 2796-2796.	1.4	6
228	Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis â€“ Results From the UK Amyloidosis Treatment Trial.. Blood, 2009, 114, 2869-2869.	1.4	13
229	In AL Amyloidosis, Both Oral Melphalan and Dexamethasone (Mel-Dex) and Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Have Similar Efficacy as Upfront Treatment.. Blood, 2009, 114, 745-745.	1.4	6
230	Early Detection of Cardiac Systolic Functional Impairment and Correlation with NT-ProBNP Change in AL Amyloidosis by Cardiac Lateral Wall Tissue Doppler S Wave.. Blood, 2009, 114, 2814-2814.	1.4	0
231	Is There a Role for Thalidomide Maintenance in the Treatment of AL Amyloidosis?.. Blood, 2009, 114, 1863-1863.	1.4	0
232	Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrology Dialysis Transplantation, 2008, 24, 676-678.	0.7	121
233	AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood, 2008, 112, 4009-4016.	1.4	73
234	Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica, 2008, 93, 295-298.	3.5	115

#	Article	IF	Citations
235	Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis.. Blood, 2008, 112, 1689-1689.	1.4	7
236	Risk-Adapted Cyclophosphamide, Thalidomide and Dexamethasone (CTD) for the Treatment of Systemic AL Amyloidosis: Long Term Outcomes among 202 Patients.. Blood, 2008, 112, 1733-1733.	1.4	3
237	Natural History and Outcome in Systemic AA Amyloidosis. New England Journal of Medicine, 2007, 356, 2361-2371.	27.0	817
238	Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood, 2007, 109, 457-464.	1.4	212
239	Eprodisate for the Treatment of Renal Disease in AA Amyloidosis. New England Journal of Medicine, 2007, 356, 2349-2360.	27.0	240
240	Paraprotein-related renal disease and amyloid. Medicine, 2007, 35, 512-515.	0.4	1
241	Amyloidosis and the lung. Chronic Respiratory Disease, 2006, 3, 203-214.	2.4	58
242	Systemic amyloidosis. Current Opinion in Pharmacology, 2006, 6, 214-220.	3.5	102
243	Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood, 2006, 107, 1227-1229.	1.4	113
244	Phenotype, Genotype, and Sustained Response to Anakinra in 22 Patients With Autoinflammatory Disease Associated With CIAS-1/NALP3 Mutations. Archives of Dermatology, 2006, 142, 1591-7.	1.4	168
245	Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. British Journal of Haematology, 2006, 134, 417-425.	2.5	84
246	Organ Transplantation in Hereditary Apolipoprotein AI Amyloidosis. American Journal of Transplantation, 2006, 6, 2342-2347.	4.7	76
247	AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome: A report of two cases. Arthritis and Rheumatism, 2006, 54, 2010-2014.	6.7	50
248	Efficacy and Safety of Bortezomib in Systemic AL Amyloidosis - A Preliminary Report.. Blood, 2006, 108, 129-129.	1.4	11
249	Hypercalcemia in a Patient With Common Variable Immunodeficiency and Renal Granulomas. American Journal of Kidney Diseases, 2005, 45, e90-e93.	1.9	18
250	Standard Oral Melphalan Chemotherapy for AL Amyloidosis Revisited Using the Serum Free Light Chain Assay.. Blood, 2005, 106, 3495-3495.	1.4	2
251	Familial amyloidotic polyneuropathy with severe renal involvement in association with transthyretin Gly47Glu in Dutch, British and American-Finnish families. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2004, 11, 44-49.	3.0	20
252	Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes and Immunity, 2004, 5, 289-293.	4.1	53

#	Article	IF	Citations
253	Spectrum of clinical features in Muckleâ€Wells syndrome and response to anakinra. Arthritis and Rheumatism, 2004, 50, 607-612.	6.7	731
254	Intermediate Dose Intravenous Melphalan and Dexamethasone Treatment in 144 Patients with Systemic AL Amyloidosis.. Blood, 2004, 104, 755-755.	1.4	7
255	Impact of Chromosomal Abnormalities Revealed by Interphase FISH on Survival in Primary Light Chain Amyloidosis.. Blood, 2004, 104, 4875-4875.	1.4	0
256	Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis and Rheumatism, 2003, 48, 2632-2644.	6.7	173
257	Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. British Journal of Haematology, 2003, 122, 78-84.	2.5	370
258	Interleukin-1â€“Receptor Antagonist in the Muckleâ€“Wells Syndrome. New England Journal of Medicine, 2003, 348, 2583-2584.	27.0	636
259	Novel Pharmacological Strategies in Amyloidosis. Nephron Clinical Practice, 2003, 94, c85-c88.	2.3	11
260	Misdiagnosis of Hereditary Amyloidosis as AL (Primary) Amyloidosis. New England Journal of Medicine, 2002, 346, 1786-1791.	27.0	621
261	Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis and Rheumatism, 2002, 46, 2445-2452.	6.7	350
262	Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis and Rheumatism, 2002, 46, 2571-2573.	6.7	121
263	Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. British Journal of Haematology, 2002, 117, 427-435.	2.5	65
264	Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature, 2002, 417, 254-259.	27.8	495
265	Improvement in renal cholesterol emboli syndrome after simvastatin. Lancet, The, 1998, 351, 1331-1332.	13.7	87
266	Visual loss with chronic meningeal and systemic inflammation. Practical Neurology, 0, , practneurol-2021-003066.	1.1	0